Curr Med Res Opin 24(1):275286 Kong F, Wu T, Dai J, Zhai Z, Cai J, Zhu Z et al (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimers disease models: a systematic review and meta-analysis of preclinical studies
20 Some limitations to these studies, however, were highlighted in responses to these publications
These are tiny sample sizes by medical research standards
The idea is that active ingredients can be absorbed through the skin, bypassing the digestive system
Keep in mind that aside from GLP-1 drugs, comprehensive obesity care can include behavioral health therapy, medically managed weight loss programs, lower-cost weight loss medications and even surgery
We understand the complexities of body mass and weight loss, and we do not determine eligibility solely based on the number on the scale